Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E.W. Cohen, Signe Friesland, Ainara Soria et al.|The Lancet|2018Cited by 1.7k
Phase 1/2a, open‐label, multicenter study of <scp>RM</scp>‐1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinomaDavid M. Cognetti, Ann M. Gillenwater, Jennifer M. Johnson et al.|Head & Neck|2021Cited by 170
PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapyMary J. Fidler, Philip Bonomi, Sanjib Basu et al.|British Journal of Cancer|2011Cited by 20